Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$32.37
+2.4%
$41.93
$13.57
$53.08
$2.21B1.94720,999 shs778,367 shs
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$17.88
+1.5%
$19.32
$10.65
$22.09
$1.26B0.27401,394 shs331,605 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$1.06
$1.32
$0.62
$3.87
$123.46M0.031.62 million shs657,783 shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$2.94
+3.2%
$4.40
$0.80
$9.62
$356.62M1.52.19 million shs857,067 shs
Tricida, Inc. stock logo
TCDA
Tricida
$0.13
$0.09
$13.85
$6.01M0.2217.62 million shs31.13 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
-2.89%-7.84%-22.93%-14.20%+16.48%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-1.40%+4.32%-11.82%-3.35%+57.94%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-2.75%-17.19%-23.74%+16.98%-70.47%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-1.04%-14.67%-33.72%-11.49%-26.74%
Tricida, Inc. stock logo
TCDA
Tricida
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arvinas, Inc. stock logo
ARVN
Arvinas
2.7266 of 5 stars
4.40.00.00.02.72.50.6
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
2.2885 of 5 stars
3.51.00.00.02.43.30.6
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.5378 of 5 stars
3.30.00.04.61.72.50.6
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
4.0755 of 5 stars
4.41.00.04.12.02.50.0
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.88
Moderate Buy$59.7384.53% Upside
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
3.00
Buy$30.0067.79% Upside
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.60
Moderate Buy$5.67434.59% Upside
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
2.71
Moderate Buy$6.29113.80% Upside
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/A

Current Analyst Ratings

Latest TCDA, KPTI, ARVN, MRSN, and KNSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$25.00 ➝ $30.00
4/23/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
4/12/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $87.00
4/2/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$28.00 ➝ $30.00
3/25/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00
3/19/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$5.00
3/1/2024
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
2/29/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $60.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$9.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$1.00 ➝ $5.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$6.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$78.50M28.17N/AN/A$11.99 per share2.70
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$270.26M4.67N/AN/A$6.23 per share2.87
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$146.03M0.85N/AN/A($1.19) per share-0.89
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$36.85M9.68N/AN/A$0.31 per share9.48
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$367.30M-$6.50N/AN/AN/A-185.09%-70.24%-31.79%5/3/2024 (Estimated)
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$14.08M$0.11162.56N/A2.78%-7.32%-6.15%7/23/2024 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$143.10M-$1.25N/AN/AN/A-97.99%N/A-50.47%5/2/2024 (Estimated)
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$171.67M-$1.50N/AN/AN/A-465.80%-282.36%-62.64%5/14/2024 (Estimated)
Tricida, Inc. stock logo
TCDA
Tricida
-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/A

Latest TCDA, KPTI, ARVN, MRSN, and KNSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2024Q1 2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-$0.14-$0.25-$0.11-$0.25$76.97 million$79.90 million    
2/29/202412/31/2023
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$0.29-$0.36-$0.07-$0.36$33.50 million$33.75 million    
2/28/2024Q4 2023
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-$0.11$0.04+$0.15-$0.27$72.31 million$83.40 million
2/28/202412/31/2023
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$0.16-$0.16N/A-$0.16$22.59 million$10.70 million    
2/27/2024Q4 2023
Arvinas, Inc. stock logo
ARVN
Arvinas
-$1.15-$2.53-$1.38-$2.53$38.91 million($43.10) million  

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.98
4.98
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/A
4.34
3.85
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
3.37
3.32
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.63
3.36
3.36
Tricida, Inc. stock logo
TCDA
Tricida
N/A
4.87
4.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
53.95%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%
Tricida, Inc. stock logo
TCDA
Tricida
N/A

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
5.23%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
54.23%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.32%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
12.50%
Tricida, Inc. stock logo
TCDA
Tricida
35.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
44568.31 million64.74 millionOptionable
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
29770.61 million32.32 millionOptionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
325116.47 million112.60 millionOptionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
123121.30 million106.14 millionOptionable
Tricida, Inc. stock logo
TCDA
Tricida
5755.67 million35.85 millionNot Optionable

TCDA, KPTI, ARVN, MRSN, and KNSA Headlines

SourceHeadline
SierraConstellation Partners Receives Industry Recognition for Work with TricidaSierraConstellation Partners Receives Industry Recognition for Work with Tricida
finance.yahoo.com - February 6 at 10:02 AM
Tricida Inc (TCDAQ)Tricida Inc (TCDAQ)
es.investing.com - January 13 at 10:29 AM
Emerging Therapies in the Treatment of Clostridium difficile-Associated DiseaseEmerging Therapies in the Treatment of Clostridium difficile-Associated Disease
medscape.com - May 30 at 8:27 AM
Vaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo FinanceVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo Finance
news.google.com - April 18 at 12:45 AM
Metabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital JournalMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital Journal
news.google.com - April 17 at 7:44 PM
Real-time PCR as a Diagnostic Tool for Bacterial DiseasesReal-time PCR as a Diagnostic Tool for Bacterial Diseases
medscape.com - April 12 at 11:47 PM
Chronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital JournalChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital Journal
news.google.com - April 10 at 8:38 AM
Chronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital JournalChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital Journal
news.google.com - April 6 at 7:54 AM
Tricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360Tricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360
news.google.com - March 24 at 11:19 PM
Alicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo FinanceAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo Finance
news.google.com - March 14 at 3:50 PM
Alicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo FinanceAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo Finance
news.google.com - March 14 at 10:49 AM
Tricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360Tricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360
news.google.com - March 6 at 10:59 PM
Troubled Adamis To Merge With Private DMK, Focus On ... - ScripTroubled Adamis To Merge With Private DMK, Focus On ... - Scrip
news.google.com - March 1 at 12:17 PM
Release Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360Release Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360
news.google.com - February 27 at 8:43 PM
Renibus Buys Tricidas Kidney Drug Veverimer In Ch. 11 Sale - Law360Renibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360
news.google.com - February 21 at 8:22 PM
STONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.com
news.google.com - February 18 at 1:53 AM
Top 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.com
news.google.com - February 18 at 1:53 AM
Tricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo Finance
finance.yahoo.com - February 14 at 7:22 PM
Rising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology NewsRising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology News
news.google.com - February 8 at 7:43 AM
Firm Retention Summary: Tricida Inc.Firm Retention Summary: Tricida Inc.
wsj.com - February 3 at 3:38 PM
Tricidas Chapter 11 Liquidation – Global Legal Chronicle - Global Legal ChronicleTricida's Chapter 11 Liquidation – Global Legal Chronicle - Global Legal Chronicle
news.google.com - January 29 at 8:47 AM
Tricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360Tricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360
news.google.com - January 26 at 6:43 PM
Weak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing SentinelWeak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing Sentinel
news.google.com - January 24 at 2:09 PM
Tricida Inc. (TCDA): This Stock is set to Soar Above its Peers - Invest ChronicleTricida Inc. (TCDA): This Stock is set to Soar Above its Peers - Invest Chronicle
news.google.com - January 24 at 9:08 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arvinas logo

Arvinas

NASDAQ:ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

NASDAQ:KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Karyopharm Therapeutics logo

Karyopharm Therapeutics

NASDAQ:KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Mersana Therapeutics logo

Mersana Therapeutics

NASDAQ:MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Tricida logo

Tricida

NASDAQ:TCDA
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.